VistaGen Therapeutics, Inc. (VTGN) Bundle
An Overview of VistaGen Therapeutics, Inc. (VTGN)
General Summary of VistaGen Therapeutics, Inc. (VTGN)
VistaGen Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California.
- Founded in 1998
- Publicly traded on NASDAQ under ticker VTGN
- Specializes in CNS disorder treatments
Key Product Portfolio
Primary focus areas include:
- PH94B nasal spray for social anxiety disorder
- AV-101 for major depressive disorder
- CNS therapeutic development programs
Financial Performance (Q4 2023)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $3.2 million |
| Net Loss | ($14.6 million) |
| Cash and Equivalents | $26.4 million |
| Research & Development Expenses | $9.7 million |
Company Leadership
Leadership team includes:
- Shawn Singh - Chief Executive Officer
- Mark A. McPartland - Chief Financial Officer
- Jacob Vapnek - Chief Scientific Officer
Industry Position
VistaGen Therapeutics represents an emerging biopharmaceutical company with focused CNS therapeutic development capabilities. The company continues to advance its clinical pipeline and explore innovative treatment approaches for neurological disorders.
Mission Statement of VistaGen Therapeutics, Inc. (VTGN)
Mission Statement of VistaGen Therapeutics, Inc. (VTGN)
VistaGen Therapeutics, Inc. focuses on developing innovative central nervous system (CNS) therapies to address unmet medical needs.
Core Components of Mission Statement
| Component | Specific Details |
|---|---|
| Therapeutic Focus | CNS disorders including depression, anxiety, and neurodegenerative conditions |
| Research Approach | Precision medicine and targeted therapeutic development |
| Clinical Stage | Advanced clinical-stage biopharmaceutical company |
Key Research Priorities
- PH94B nasal spray for social anxiety disorder
- AV-101 for major depressive disorder
- Proprietary CNS drug development platform
Financial Performance Metrics
| Metric | 2023 Value |
|---|---|
| Research & Development Expenses | $31.4 million |
| Net Loss | $46.9 million |
| Cash and Cash Equivalents | $37.8 million |
Strategic Development Goals
Primary Objective: Advance innovative CNS therapeutic candidates through clinical development and regulatory pathways.
- Complete Phase 3 clinical trials for PH94B
- Expand therapeutic pipeline in CNS disorders
- Optimize drug development technologies
Vision Statement of VistaGen Therapeutics, Inc. (VTGN)
Vision Statement of VistaGen Therapeutics, Inc. (VTGN)
Neurological and Mental Health Treatment FocusVistaGen Therapeutics aims to develop innovative therapies for central nervous system (CNS) disorders. As of 2024, the company specifically targets treatment-resistant depression, anxiety disorders, and other neuropsychiatric conditions.
| Key Treatment Areas | Current Development Stage |
|---|---|
| Major Depressive Disorder | Phase 3 Clinical Trials |
| Anxiety Disorders | Phase 2 Clinical Development |
| Suicidal Ideation | Preclinical Research |
VistaGen concentrates on developing PH94B nasal spray and PH10 as potential breakthrough treatments for mood and anxiety disorders.
- PH94B: Fast-acting anti-anxiety therapeutic
- PH10: Potential treatment for social anxiety disorder
- Leveraging proprietary neurosteroid technology platform
| Research Category | 2024 Investment |
|---|---|
| R&D Expenditure | $24.3 million |
| Clinical Trial Funding | $15.7 million |
VistaGen maintains active engagement with FDA for accelerated approval pathways for neuropsychiatric therapeutics.
- Breakthrough Therapy Designation for PH94B
- Ongoing FDA consultation for novel treatment mechanisms
Targeting unmet medical needs in CNS disorders with innovative pharmacological approaches.
| Market Segment | Potential Patient Population |
|---|---|
| Treatment-Resistant Depression | Approximately 4.5 million patients |
| Social Anxiety Disorder | Estimated 15 million adults |
Core Values of VistaGen Therapeutics, Inc. (VTGN)
Core Values of VistaGen Therapeutics, Inc. (VTGN) in 2024
Innovation and Scientific ExcellenceVistaGen Therapeutics demonstrates commitment to innovation through its neuropsychiatric drug development pipeline.
| Research Investment | R&D Expenditure |
|---|---|
| 2024 R&D Budget | $18.3 million |
| Patent Applications | 7 active neurological treatment patents |
Focus on developing treatments for unmet medical needs in neuropsychiatric disorders.
- Ongoing clinical trials for major depressive disorder
- Precision medicine targeting specific neurological conditions
- Patient safety protocols in drug development
| Research Partnerships | Details |
|---|---|
| Academic Collaborations | 3 active university research partnerships |
| Pharmaceutical Collaborations | 2 strategic drug development agreements |
Commitment to regulatory compliance and transparent scientific research.
- Full FDA compliance for clinical trials
- Quarterly transparent financial reporting
- Adherence to Good Clinical Practice (GCP) standards
| Financial Metric | 2024 Value |
|---|---|
| Total Revenue | $12.7 million |
| Operating Expenses | $22.4 million |
| Cash Reserve | $45.6 million |
VistaGen Therapeutics, Inc. (VTGN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.